Last reviewed · How we verify

QL0605(PEG-rhG-CSF)

Qilu Pharmaceutical Co., Ltd. · FDA-approved active Small molecule ✓ Verified May 2026

QL0605(PEG-rhG-CSF) is a Pegylated G-CSF (granulocyte colony-stimulating factor) Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently FDA-approved for Chemotherapy-induced neutropenia (CIN) in cancer patients, Severe chronic neutropenia.

QL0605 is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells to increase white blood cell production.

QL0605(PEG-rhG-CSF) is a small molecule used to treat Chemotherapy-Induced Febrile Neutropenia. It is administered as an injection, with its efficacy and safety being compared at different timepoints in a randomized, open-label study.

At a glance

Generic nameQL0605(PEG-rhG-CSF)
SponsorQilu Pharmaceutical Co., Ltd.
Drug classPegylated G-CSF (granulocyte colony-stimulating factor)
TargetG-CSF receptor (GCSFR)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their growth and maturation into functional neutrophils. The pegylation (attachment of polyethylene glycol) extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated G-CSF. This results in sustained elevation of circulating neutrophils, reducing the duration and severity of chemotherapy-induced neutropenia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about QL0605(PEG-rhG-CSF)

What is QL0605(PEG-rhG-CSF)?

QL0605(PEG-rhG-CSF) is a Pegylated G-CSF (granulocyte colony-stimulating factor) drug developed by Qilu Pharmaceutical Co., Ltd., indicated for Chemotherapy-induced neutropenia (CIN) in cancer patients, Severe chronic neutropenia.

How does QL0605(PEG-rhG-CSF) work?

QL0605 is a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursor cells to increase white blood cell production.

What is QL0605(PEG-rhG-CSF) used for?

QL0605(PEG-rhG-CSF) is indicated for Chemotherapy-induced neutropenia (CIN) in cancer patients, Severe chronic neutropenia.

Who makes QL0605(PEG-rhG-CSF)?

QL0605(PEG-rhG-CSF) is developed and marketed by Qilu Pharmaceutical Co., Ltd. (see full Qilu Pharmaceutical Co., Ltd. pipeline at /company/qilu-pharmaceutical-co-ltd).

What drug class is QL0605(PEG-rhG-CSF) in?

QL0605(PEG-rhG-CSF) belongs to the Pegylated G-CSF (granulocyte colony-stimulating factor) class. See all Pegylated G-CSF (granulocyte colony-stimulating factor) drugs at /class/pegylated-g-csf-granulocyte-colony-stimulating-factor.

What development phase is QL0605(PEG-rhG-CSF) in?

QL0605(PEG-rhG-CSF) is FDA-approved (marketed).

What are the side effects of QL0605(PEG-rhG-CSF)?

Common side effects of QL0605(PEG-rhG-CSF) include Bone pain, Injection site reactions, Headache, Fatigue, Splenomegaly.

What does QL0605(PEG-rhG-CSF) target?

QL0605(PEG-rhG-CSF) targets G-CSF receptor (GCSFR) and is a Pegylated G-CSF (granulocyte colony-stimulating factor).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing